The Selective Estrogen Receptor a Agonist Org 37663 Induces Estrogenic Effects but Lacks Antirheumatic Activity.

The article presents a study which examines the effects and safety of selective estrogen receptor α (ERα) agonist Org 37663 in rheumatoid arthritis (RA) patients. It states that a 10-week, randomized, and proof-of-concept trial was initiated in RA postmenopausal female patients who receive background treatment with methotrexate or sulfasalazine. The results showed that Org 37663 was safe and well tolerated, but was not effective in influencing the disease activity in RA patients.